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these tumors as a distinct clinical entity. Today, howev-
er, the optimum therapy for carcinomas of the superior
sulcus remains controversial.
The major impediment to the resolution of issues
regarding treatment is the low incidence of these
tumors. Owing to this, series involving tumors of the
superior pulmonary sulcus are generally from single
institutions, involve small numbers of patients, and are
reported retrospectively.4-13 Thus the specific roles for
radiation therapy and chemotherapy and the allegation
of a unique pattern of metastasis remain uncertain.
Recently reported series, however, suggest that the pat-
tern of failure of these tumors is similar to that of bron-
chogenic carcinomas in general.5-13 As a result, superi-
B ronchogenic carcinomas arising from the superiorpulmonary sulcus present with a distinctive constel-
lation of symptoms first described in 1838 by Hare.1 In
1924, and with an update in 1932, Pancoast2,3 identified
Objectives: Our goal was to assess patient survival and response to treat-
ment for superior sulcus tumors treated with combined radiation ther-
apy and surgery when possible, or with radiation alone when surgery
was not possible. Methods: Seventy-three patients were treated for pri-
mary non–small cell carcinoma of the superior pulmonary sulcus.
Thirty-four patients received combined resection and irradiation.
Thirty-nine patients who had extensive primary disease, distant metas-
tases, or who were medically unfit for surgery were treated with radia-
tion alone. Thirty-one patients (91%) assigned to the resection/irradia-
tion group completed treatment. Combined therapy patients routinely
received 40 Gy before the operation, with additional postoperative irra-
diation based on the surgical findings. Results: Overall survival at 5 years
was 19% and disease-specific survival was 20% for all patients. Overall
survival and disease-specific survival at 5 years for the resection/irradi-
ation group were 33% and 38%, respectively. Significant indicators of
poor prognosis included unresected primary disease, low performance
score, T4 stage, or positive node status. Eighty-two percent of the
patients who received irradiation alone were treated with palliative
intent. Freedom from local-regional progression, achieved initially in
66% of these patients, was associated with a median survival of 8
months. Median survival for 7 patients considered for definitive irradi-
ation was 25 months. During the first 18 months, distant failures
occurred in approximately 35% of patients in each treatment group.
Conclusions: Selection of medically fit patients with resectable disease for
combined surgery and aggressive radiation therapy resulted in a high
likelihood of local control. Overall survival for the resection/irradiation
group was significantly poorer for patients with T4 stage, nodal disease,
or Horner’s syndrome. Distant metastases eventually developed in 56%
of patients undergoing resection. Median survival in the resection/irra-
diation group was significantly prolonged for those patients who could
tolerate high-dose radiation treatment. (J Thorac Cardiovasc Surg
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or sulcus tumors are currently included with other stage
IIIA/B non–small cell tumors for the intergroup study
of neoadjuvant, adjuvant, or definitive chemotherapy
and irradiation.
The present study, also retrospective from a single
institution, includes not only patients treated for cure,
but also those who received palliation. By including the
entire institutional experience, the current study pro-
vides additional information about the natural history
and pattern of failure of superior sulcus tumors. 
During the period encompassed by this review,
patients received surgical evaluation resulting in a rec-
ommendation for either combined surgery and irradia-
tion or irradiation alone. Combined treatment was rou-
tinely recommended for patients with T3 primary
tumors, negative results of mediastinoscopy, and no
evidence of distant disease. Patients with T4 tumors or
N2 nodal status (with a few exceptions) received radia-
tion therapy alone. Although the population of patients
includes both those with resected and those with unre-
sected tumors, the study does not attempt to compare
treatments. Instead, we present the results of a consis-
tent set of treatment policies aimed at an aggressive
attempt to secure local control in selected patients.
Patients and methods
Records reviewed for this retrospective study included
those of all patients seen at Massachusetts General Hospital
from January 1975 to January 1992 who had a diagnosis of
lung cancer involving an upper lobe. From this cohort, the
following patients were selected for inclusion: those coded as
having non–small cell superior sulcus tumors, Pancoast
tumors, or chest wall involvement and patients whose signs
and symptoms included shoulder pain, upper extremity weak-
ness, or Horner’s syndrome. Patients with painful apical
tumors were excluded when the tumor was completely con-
tained within the visceral pleura, the painful site was limited
to the anterior chest wall, or signs and symptoms of
Pancoast’s syndrome were absent. These criteria identified 73
patients.
Treatment selection. The assigned treatments are shown
schematically in Fig 1. Those patients without evidence of
regional lymph node involvement, direct mediastinal inva-
sion, extensive involvement of a vertebral body, or invasion
into a neural foramina were treated for cure with combined
resection and irradiation (the S+RT group). Most of these
patients received preoperative irradiation followed by resec-
tion. Patients who did not meet these criteria received radia-
tion treatment alone (the RT group), usually with palliative
intent. In the palliated group, 16 patients had regional lymph
node involvement, 15 had distant metastases either from the
onset or discovered within the first 30 days of treatment, and
for 14 patients the primary disease was too extensive to allow
control by definitive irradiation. In the latter instance, the pri-
mary tumor was multilobar, involved a large region of the
chest wall, or was larger than 10 cm. In all, 34 patients were
selected for combined surgery plus irradiation, whereas 39
received radiation therapy alone. 
Of the 34 patients in the S+RT group, 27 received preoper-
ative irradiation with 11 receiving additional postoperative
radiation therapy. Seven patients treated before 1982 received
only postoperative irradiation. Three patients scheduled for
resection plus irradiation did not complete their treatment. All
3 completed preoperative irradiation, but afterward 2 had dis-
tant disease develop and 1 died of pneumonia. An additional
patient died of pneumonia within 30 days of completing post-
operative irradiation. This process, beginning as a pneumoni-
tis restricted to the radiation portal, represents the sole radia-
tion complication. The surgical techniques have been detailed
elsewhere.9 Although we currently use an anterior approach
when feasible, for the present series all tumors were resected
en bloc via the posterior approach.
Fig 1. Patient grouping according to the assigned treatment. RT, Radiation therapy; NSCCa, non–small cell car-
cinoma. *Eleven patients also received postoperative radiation therapy.
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Pretreatment evaluation. The initial evaluation of each
patient routinely included history and physical examination,
complete blood count, liver and renal function studies, and
chest radiography. Other diagnostic work-up, reported as a
percentage of the 73 patients in the total population, was per-
formed as follows: computed tomography (CT) of the thorax
(85%), radionuclide bone scan (93%), anterior medi-
astinoscopy or Chamberlain procedure (all patients undergo-
ing resection and 66% of the total group), bronchoscopy
(66%), and CT scan or radionuclide scan of the head (48%).
Irradiation. Radiation therapy was administered initially
through parallel-opposed, anteroposterior-posteroanterior
ports using megavoltage equipment. Fifty-eight patients were
treated with 10-MV photons, 5 with 2-MV photons, 10 with
cobalt 60, and 1 patient was treated with a combination of
photon and proton irradiation. The treatment port routinely
included the tumor with a 2-cm margin, ipsilateral hilum,
mid-upper mediastinum, and ipsilateral or bilateral supra-
clavicular regions. The spinal cord was limited to 45 Gy.
Fourteen patients were treated twice daily with fraction sizes
ranging from 1.4 to 1.8Gy. All other patients were treated
daily at 1.8 to 2 Gy per exposure. Both fields were treated at
each session, except in the 5 patients treated with 2-MV pho-
tons, for whom one field was treated each day. Typically, 40
Gy was given before the operation (range 30–45 Gy) with an
additional 20 Gy given after the operation when lymph nodes
were pathologically involved or when surgical margins were
positive (diseased) or considered “close” by the reviewing
pathologist. Seven patients treated before 1985 received only
postoperative irradiation (range 50–64 Gy). For patients
treated with radiation therapy alone, the radiation dose was
dependent on individual physician preference.
Tumor characteristics. Tumor histologic type and staging
are shown in Table I. Eighty-two percent of the patients treat-
ed with surgery plus irradiation had stage T3 disease, and
only 18% had stage N1–N3 disease. For the patients who
received irradiation alone, however, only 62% had stage T3
disease, whereas 46% had N1–N3 disease. The N0 findings
for the patients in the RT group were based on medi-
astinoscopy. Patients without clinical or radiographic evi-
dence of adenopathy were considered to have NX disease.
The distributions of specific histologic types were similar for
the RT and S+RT groups. Although the average size of the
primary tumor treated by irradiation alone was greater, these
determinations were radiologic for the patients treated with
radiation alone and via radiologic information or pathologic
review, usually after preoperative radiation therapy, for the
resected lesions. For the S+RT group the largest diameter
recorded is reported.
Data analysis. Response to treatment was analyzed for
local control, distant metastasis, and survival. Outcome was
assessed on the basis of the patient’s originally assigned treat-
ment. Local control was scored as freedom from clinical or
radiographic evidence of local or regional progression.
Survival values, determined by the life table method,14
involved the period from the time of diagnosis until initial
failure or death. For disease-specific survival, 4 patients with
no evidence of active cancer were censored because of death
from unrelated causes. Three patients were from the com-
bined S+RT group and 1 from the RT group. Follow-up was
complete at 5 years or death, except for 2 patients who were
lost to follow-up after 49 and 51 months, respectively. The
Cox proportional hazard model was used to test the interac-
tion of prognostic factors and treatment parameters.
Proportional differences were assessed for significance by the
c
2 test. The Welch modified Student t test was used to evalu-
ate differences in sample mean values.
Results
From 1975 to 1992, 73 patients were referred to
Massachusetts General Hospital for treatment of
non–small cell carcinomas originating in the superior
Table I. Tumor characteristics
S+RT RT
No. of No. of 
Characteristic patients % patients %
Non–small cell cancer 34 39
T stage
T3 28 82 24 62
T4 6 18 15 38
N stage
NX 0 19 49
N0 28 82 2
N1 2 4 10
N2 3 9 23
N3 1 5 13
Maximum lesion 5.2 cm 5.7 cm
diameter (s ) (1.4 cm) (2.2 cm)
Histology
Non–small cell carcinoma
Adenocarcinoma 6 19 5 15
Large cell 12 38 14 42
Squamous cell 14 44 14 42
Unspecified 2 6
S+RT, Surgery plus radiation therapy; RT, radiation therapy.
Table II. Patient characteristics
Characteristic S+RT RT
Patients (n) 34 39
Median age (y) 57 62 
Average KPS (s ) 82 (8.6) 74 (21.6)
Weight loss (>10%) 7 (21%) 17 (44%)
Smoking history >20 packs/year 19 (56%) 24 (62%)
Presentation
Horner’s syndrome 6 (21%) 15 (35%)
Shoulder pain* 27 (90%) 37 (97%)
Arm weakness† 8 (24%) 22 (56%)
S+RT, Surgery plus radiation therapy; RT, radiation therapy; KPS, Karnofsky
performance score.
*Includes scapular pain.
†Ipsilateral upper extremity weakness noted on any examination before treatment.
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pulmonary sulcus. Forty-seven patients had stage IIIA
disease and 26 had stage IIIB disease. Twenty-four
patients (33%) had pathologic or CT evidence of lym-
phadenopathy. Thirty-three percent reported a greater
than 10% weight loss, and the average Karnofsky per-
formance score was 76.15
Comparison of patient characteristics for S+RT
versus RT groups. Thirty-four patients were treated
with a combination of irradiation and resection.
Criteria for their selection are listed in the Patients and
methods section. Patients who did not meet these crite-
ria or who had evidence of distant metastasis, regional
lymph node involvement, mediastinal disease, exten-
sive vertebral body involvement, or other unresectable
disease received irradiation alone. Characteristics of
the patients in each treatment group are shown in Table
II. Patients in both groups were of similar average age
and were equally likely to have had a painful brachial
plexopathy. Patients meeting the criteria for resection,
however, more frequently had stage IIIA disease, had a
significantly higher Karnofsky status (P = .0004), were
less likely to have reported weight loss (P = .005), and
infrequently had Horner’s syndrome or motor deficits
involving the brachial plexus.
Survival for the combined group. Overall survival
for the entire population is shown in Fig 2. There was
no significant difference between overall survival and
disease-specific survival for this population. The 5-year
figures for overall and disease-specific survival were
19% and 20%, respectively. The results of univariate
analysis for overall survival are listed in Table III.
Overall survival was greater for patients with
Karnofsky performance status of 70 or greater (P =
.01), patients with stage T3 disease (P = .02), and node-
negative patients (P = .00002). Disease-specific sur-
vival was significantly greater for the same parameters:
Karnofsky status of 70 or greater (P = .03), stage T3
disease (P = .01), and no adenopathy (P = .00002).
Patients with greater than a 10% weight loss also
showed a trend toward lower overall survival.
Survival and local control for patients undergoing
resection. Overall survival and disease-specific sur-
vivals for all 34 patients selected for resection are
shown in Fig 3. Overall survival for these patients was
42% at 2 years and 33% after 5 years. The correspond-
ing disease-specific survival values were 49% and
38%, respectively. Local control for this group, shown
in Fig 4, was 80% after 5 years. Isolated local recur-
rences as the first site of recurrence were noted in only
3 patients. Univariate analysis, shown in Tables III and
IV, for the patients undergoing resection demonstrated
that overall survival but not local-regional control was
significantly better for node-negative patients (P = .05
and P = .55, respectively). The absence of Horner’s
syndrome was also associated with significantly
greater overall survival (P = .03). Patients with negative
(disease-free) surgical margins and T3 status had fewer
local-regional failures.
Multivariate analysis. The results of multivariate
analysis are shown in Table V. Multivariate analysis of
prognostic factors for overall survival identified lym-
phadenopathy as the only significant factor (P = .0055).
For local-regional control, tumor size (P = .031), T
stage (P = .017), and lymphadenopathy (P = .042) were
all significant predictors. When analysis was restricted
to the S+RT group, no prognostic or treatment-related
factors were significant.
Impact of positive microscopic margins. Within
the S+RT group, 6 patients were considered to have
stage T4 disease because of vertebral body involvement
(4 patients), great vessel involvement (1 patient), or
mediastinal extension (1 patient). Of these patients, 5
had microscopic evidence of positive margins. Two
Table III. Univariate analysis: Overall survival
P value (HR and CI)*
Parameter All patients S+RT group
KPS
<70 .01 .95
‡ 70 (.708, .54-.93)
Ten percent weight loss .16 .86
Plexopathy .97 .24
Horner’s syndrome .29 .03 (1.87, 1.0-3.49)
T stage
T3 vs T4 .02 (1.37, 1.05-1.78) .51
Nodal status
All patients
N0 NX .00002
N+ (3.26, 1.85-5.73)
S+RT patients†
N0 .05
N+ (1.63, 1.0-2.63)
Fractionation
Standard vs ND .18
hyperfractionated
Tumor size
≤5 cm .24 .48
>5 cm
Margin status
Positive ND .26
Negative
S+RT, Surgery plus radiation therapy; KPS, Karnofsky performance score;
N0, node-negative patients; N+, node-positive patients; NX, nodal status
uncertain; ND, not done.
*P values are the result of Cox proportional hazard analysis; the hazard ratio
(HR) and confidence intervals (CI) are shown when the P value is ≤ .05.
†For patients not undergoing resection, positive nodal status was determined
by CT or mediastinoscopy. Patients with no radiographic evidence of node
positivity were considered to be NX.
1090 Hagan et al The Journal of Thoracic and
Cardiovascular Surgery
June 1999
additional patients, with stage T3 disease, also had
microscopically positive margins. Ultimately, 2 of
these 7 patients with positive margins had local recur-
rence, 1 had distant disease, and the disease status of
another was uncertain. A microscopically positive sur-
gical margin did not significantly affect survival but, on
Fig 2. Kaplan-Meier actuarial survival curves for the entire patient group. Confidence intervals (95%) are shown
as broken lines.
Fig 3. Kaplan-Meier actuarial overall and disease-specific survival curves for the patients undergoing combined
surgery/radiation therapy. Confidence intervals were omitted to avoid confusion. 
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univariate analysis, was associated with a greater like-
lihood of local-regional recurrence (P = .02). In multi-
variate analysis of local-regional failures, however,
margin status was not significant (P = .34) when the
sample was controlled for T stage. 
Patients receiving irradiation alone (RT group).
Thirty-nine patients were treated with radiation alone.
For these patients overall survival after 5 years was 7%.
Palliative response. Most patients who were not
selected for resection (32/39 patients) received radia-
tion therapy with the goal of providing durable pallia-
tion. Initial local control (scored as freedom from local
progression) was achieved in 66% of these patients.
The median duration of control was 15 months. Median
survival for the palliated group, however, was only 34.8
weeks. 
Definitive irradiation. Definitive irradiation was
attempted in 7 patients in the RT group. These patients
had no evidence of distant disease, had a primary tumor
6 cm or smaller, and had no sites of bulky adenopathy
identified radiologically. For 1 patient with T4 N2 dis-
ease, spinal cord proximity limited the radiation dose to
54 Gy. Local control was not achieved. One patient
(stage T3 N0 disease) for whom proximity of the spinal
cord was not an issue received 73 Gy. This patient sur-
vived for 67 months, having local-regional treatment
failure after 53 months. For the remaining 5 patients the
spinal cord dose was partially limiting. The average
tumor dose was 65 Gy. Median survival for this group
was 25.2 months (range 12–51 months). Local failure
eventually developed in 5 of 6 patients in this group for
whom local control information was available.
Distant metastasis. The primary mode of treatment
failure for both treatment groups was through distant
disease. Actuarially, 47% of patients receiving com-
bined surgery and irradiation had distant metastases
within the first 5 years. The initial site of distant disease
for 5 patients was the brain. Failure first occurred in the
contralateral lung, adrenals, and skin for 1 patient each
and was unrecorded in 2 patients. The median time to
the appearance of distant metastasis in the S+RT
patient group was 17 months. In the RT group, howev-
er, the median time to appearance of distant disease
was less than 3 months. For each treatment group, dis-
tant failure was seen in approximately 35% of patients
in the first 18 months. The S+RT group, by virtue of its
greater proportion of patients with local control and
hence patients at risk for distant failure, provided evi-
dence for late distant failures. The last was recorded 71
months after the original diagnosis.
Lymphadenopathy and distant disease. For
patients in the S+RT group, lymph node disease was
associated with a greater risk of distant failure, but not
local-regional failure. Overall, distant metastases even-
tually developed in 60% of patients with positive
lymph nodes, whereas only 30% of node-negative
Fig 4. Kaplan-Meier curve for local control at the first site of failure (actuarial) for patients treated with surgery
and irradiation.
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patients were similarly affected. Twenty-seven patients
in the S+RT group, for whom pathologic evaluation of
lymph node status was uniformly obtained, could be
evaluated for distant disease. Distant disease occurred
in 22% of those who were node negative and in all 4
patients who were lymph node positive. Regardless of
the treatment group, no patient with lymphadenopathy
survived longer than 22 months.
Discussion 
This series includes all patients with a primary
non–small cell carcinoma of the superior pulmonary
sulcus treated at the Massachusetts General Hospital
from 1975 to 1992. Every effort was made to exclude
patients with apical tumors or patients whose tumor
secondarily invaded the superior sulcus. All tumors
were staged either T3 or T4, with the chest wall repre-
senting the most common site of extension. The nodal
incidence, which for superior sulcus tumors varies con-
siderably from series to series,10-13 was 18% for
patients undergoing resection and 33% overall. In 15
patients (20%) distant metastases were either present
on admission or developed within 30 days of diagnosis.
Patients were offered combined surgery and irradia-
tion if they had resectable primary disease, had no con-
traindication for irradiation, had no evidence of distant
disease, and had mediastinoscopic results negative for
involvement. This selection resulted in 3 distinct
patient populations illustrated in Fig 1.
This degree of selection is typical of those series that
include an institution’s entire experience. In the 6 other
series that report results of both palliative and curative
treatments, the rate of resection varied from 29% to
58%.7,12,13,16,17 Overall 5-year survival for the patients
undergoing resection from these series averaged 31%.
Survival for the largely palliatively treated patients not
undergoing resection was 5% from the same series.
These results are similar to the values reported here (5-
year overall survival of 33% with a resection rate of
42%, and a 7% 5-year survival for the patients not hav-
ing resection). Interestingly, none of these results for
patients undergoing resection differs significantly from
the results of the seminal series reported by Paulson5
and Maggi and colleagues18 (35% 5-year survival and
a 64% rate of resection). 
The obvious aim of combined treatment is to
improve survival by securing local-regional control of
disease. When extension to adjacent structures impedes
surgical resection of the tumor, preoperative irradiation
has proven useful. Generally, irradiation in the preop-
erative setting reduces morbidity by requiring lower
radiation doses and smaller treatment volumes.
Preoperative irradiation also reduces the likelihood of
Table IV. Univariate analysis: Local-regional con-
trol*
P value (HR and CI)
Parameter All patients S+RT group
KPS
<70 .0008 .62
‡ 70 (.505, .337-.759)
Ten percent weight loss .03 (.636, .421-.96) .80
Plexopathy .81 .59
Horner’s syndrome .95 .53
T stage
T3 .005 .02
T4 (1.73, 1.2-2.5) (3.41, 1.1-10.6)
Nodal status
All patients
N0 NX 1.2 · 10–6
N+ (9.23, 3.1-27.5)
S+RT patients
N0 .55
N+
Fractionation
Standard vs .02 (.503, .244-1.03) .70
hyperfractionation
Tumor size (cm)
≤5 cm .01 .19
>5 cm (1.84, 1.129-3.00)
Margin status
Positive ND .02
Negative (3.41, 1.1-10.6)
HR, Hazard ratio; CI, confidence intervals; S+RT, Surgery plus radiation ther-
apy; RT, radiation therapy; KPS, Karnofsky performance score.
*Scored as freedom from local progression. 
Table V. Multivariate analysis: All patients
P value (HR and CI)*
Parameter Overall survival Local control
KPS
<70 .07
‡ 70 (.775, .59-1.02)
Tumor size (cm)
≤5 cm .031
>5 cm (1.985, 1.064-3.70)
T stage
T3 .017
T4 (1.688, 1.10-2.59)
Nodal status
N0 NX .0055 .042
N+ (2.48, 1.31-4.71) (6.868, 1.833-25.73)
KPS, Karnofsky performance score; N0, node-negative patients; N+, node-
positive patients; NX, nodal status uncertain.
*P values are the result of Cox proportional hazard analysis; the hazard ratio
(HR) and confidence intervals (CI) are shown when the P value is ≤.05.
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spilling viable tumor cells and may improve the
resectability. In addition to superior sulcus tumors, the
resection of locally advanced carcinomas of the
breast,19 rectum,20 and esophagus21 and of sarcomas22
has been assisted through this maneuver. 
Altered fractionation schedules for the preoperative
irradiation, specifically, hyperfractionation and acceler-
ated hyperfractionation, are frequently associated with
improved local control.23-25 For this series, the irradia-
tion component evolved from daily exposures (deliver-
ing 30 Gy before the operation) to an aggressive pro-
gram consisting of accelerated hyperfractionation
delivering 40 Gy. 
Before the routine use of CT, few reports attempted to
quantify local control of tumors involving the superior
sulcus. In recent reports, however, local control has been
remarkably similar for series reporting results of com-
bined irradiation and resection. Komaki and associates11
reported 86% local control for combined modality
patients at the M. D. Anderson Hospital, and Maggi and
colleagues18 reported a similar figure, 85%, from the
Turin series. Remmen and coworkers26 have reported 2
local failures in 5 years in a small series (10 patients at
risk) from Nijmegen and Groesbeek. In the present
series, local control was achieved in 91% of patients
undergoing resection, and for 80% of the patients, local
control was maintained for more than 5 years. No local
failures were documented for the 11 patients in the
S+RT group who received irradiation twice daily. 
When the surgical margin was close or positive, post-
operative irradiation was delivered. In previous reports,
the use of postoperative irradiation to salvage partially
resected superior sulcus tumors has been largely unsuc-
cessful. Series from the University of California at Los
Angeles27 and from Turin18 reported no 5-year sur-
vivors after postoperative irradiation. At the Memorial
Sloan-Kettering Cancer Center, although patients with
partially resected tumors routinely received postopera-
tive brachytherapy, their 5-year survival was less than
10%28 and not different from the survival of patients
not undergoing resection. In the present series, howev-
er, 14 patients with close or positive margins received
postoperative irradiation. Eleven had no local-regional
failures and 7 patients were 5-year survivors.
Patients whose primary tumors were unresected
received irradiation alone. Although the intent of this
treatment was not always clearly stated, many patients
received low-dose palliative treatment. However, a
small group of these patients was potentially curable.
Seven patients were medically fit, and their primary
disease, which was relatively small (<6 cm), was not
associated with distant disease or bulky adenopathy. In
6 of these patients, either the radiation dose or the field
size was limited because of proximity to the spinal
cord. Treatment failed locally in 5 of these 6 patients.
The single patient who received adequately placed
high-dose irradiation survived more than 5 years but
had a late local failure. These results illustrate both the
need for and the difficulty in delivering definitive irra-
diation to the superior sulcus.
It is clear from this series, and the several others
described in this report, that through the use of aggres-
sive local treatment long-term local-regional control
can be achieved for a high percentage of patients who
are candidates for resection. Unfortunately, distant
metastases will eventually develop in approximately
half of these patients. Thus, in the absence of earlier
diagnosis, improved long-term survival will require
better systemic therapy.
In the setting of carcinomas of the superior sulcus,
chemotherapy data are scarce, preventing meaningful
interpretation. For example, Martinez-Monge and
coworkers29 reported a 56% 4-year survival for 18
patients treated with preoperative chemotherapy and
radiation therapy, but Ginsberg and associates28 report-
ed no long-term survivors from a group of 10 patients
treated with neoadjuvant chemotherapy.
There is evidence, however, that chemotherapy
increases survival in the setting of other IIIA/IIIB
non–small cell lung cancers. Positive results have been
reported from 2 trials of preoperative platinum-based
chemotherapy and radiation therapy.30,31 These encour-
aging results have established the basis for a current
intergroup trial studying induction chemotherapy and
radiation therapy for carcinomas of the superior sulcus. 
Our current approach for tumors of the superior sul-
cus incorporates 2 cycles of platinum-based chemother-
apy in the neoadjuvant setting. This is followed by twice
daily irradiation in a concomitant boost format. Three to
4 weeks later the tumor is resected en bloc either via the
posterior approach or, when appropriate, through an
anterior approach. 
In summary, resection and adjuvant irradiation pro-
duced excellent local control of superior sulcus tumors.
This degree of regional disease control was associated
with a 5-year overall survival of 33%. Although few
patients had positive surgical margins, adjuvant irradi-
ation appears to have controlled the disease in most
patients. Distant metastasis was the most frequent
mode of first failure.
Both the high percentage of patients receiving only
palliative care and the dismal prognosis for patients
with positive lymph nodes of high T stage are consis-
tent with the outcome for bronchogenic carcinomas
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from other sites. Thus the discordance of high survival
associated with lesions of high T stage, for which supe-
rior sulcus tumors are known, appears to be more of an
artifact of the staging system than evidence of an
unusual natural history.
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